Laboratory Corp. of America Holdings (NYSE:LH) saw some unusual options trading activity on Wednesday. Stock traders bought 2,273 call options on the company. This is an increase of approximately 2,005% compared to the typical daily volume of 108 call options.

LH has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. Wolfe Research initiated coverage on shares of Laboratory Corp. of America in a research report on Tuesday, April 2nd. They issued an “underperform” rating on the stock. ValuEngine raised shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research report on Monday, March 11th. UBS Group initiated coverage on shares of Laboratory Corp. of America in a research report on Thursday, January 17th. They issued a “buy” rating and a $169.00 price target on the stock. Finally, Barclays lifted their price target on shares of Laboratory Corp. of America from $165.00 to $173.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $175.50.

Shares of Laboratory Corp. of America stock opened at $144.16 on Thursday. The firm has a market capitalization of $15.06 billion, a PE ratio of 13.08, a P/E/G ratio of 1.80 and a beta of 1.15. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.51. Laboratory Corp. of America has a 1 year low of $119.38 and a 1 year high of $190.35.

Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, February 7th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.48 by $0.04. The business had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.78 billion. Laboratory Corp. of America had a net margin of 8.43% and a return on equity of 17.05%. Laboratory Corp. of America’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the company posted $2.45 earnings per share. On average, sell-side analysts anticipate that Laboratory Corp. of America will post 11.22 earnings per share for the current year.

In other news, Director R Sanders Williams sold 1,038 shares of Laboratory Corp. of America stock in a transaction that occurred on Wednesday, February 13th. The shares were sold at an average price of $147.00, for a total value of $152,586.00. Following the transaction, the director now owns 8,924 shares of the company’s stock, valued at $1,311,828. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.74% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Commonwealth Bank of Australia boosted its stake in Laboratory Corp. of America by 21.3% during the fourth quarter. Commonwealth Bank of Australia now owns 10,902 shares of the medical research company’s stock worth $1,373,000 after buying an additional 1,911 shares in the last quarter. Norges Bank acquired a new stake in Laboratory Corp. of America during the fourth quarter worth $120,695,000. BRYN MAWR TRUST Co boosted its stake in Laboratory Corp. of America by 8.1% during the fourth quarter. BRYN MAWR TRUST Co now owns 35,695 shares of the medical research company’s stock worth $4,510,000 after buying an additional 2,666 shares in the last quarter. Stone Ridge Asset Management LLC boosted its stake in Laboratory Corp. of America by 8.7% during the fourth quarter. Stone Ridge Asset Management LLC now owns 5,934 shares of the medical research company’s stock worth $750,000 after buying an additional 475 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in Laboratory Corp. of America by 7.3% during the fourth quarter. Nordea Investment Management AB now owns 2,120,509 shares of the medical research company’s stock worth $267,945,000 after buying an additional 143,426 shares in the last quarter. Institutional investors and hedge funds own 91.51% of the company’s stock.

WARNING: “Laboratory Corp. of America Sees Unusually High Options Volume (LH)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2019/04/18/laboratory-corp-of-america-sees-unusually-high-options-volume-lh.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Further Reading: Why is cost of goods sold important?

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.